On Apr. 24, 2019, GSK announced $100 million of new investment in its manufacturing site in Hamilton, Montana to expand the production capacity of key components of the adjuvant system used in several of GSK’s vaccines, including SHINGRIX, which was approved by the U.S. Food and Drug Administration (FDA) in October 2017.

The Hamilton vaccines facility manufactures components of GSK’s essential adjuvant technologies, which this investment will expand further. Hamilton is one of nine GSK manufacturing sites in the United States, and 86 sites globally, that produce a variety of prescription medicines, vaccines and consumer healthcare products.

GSK is dedicated to investing in and supporting communities by creating high-quality jobs in areas like R&D and manufacturing. Over the next few years, the Hamilton site expansion is expected to add a combination of temporary construction and contracting jobs, as well as new permanent positions, including scientists, engineers and manufacturing and quality professionals. Hamilton is one of nine GSK manufacturing sites in the United States, and 86 sites globally, that produce a variety of prescription medicines, vaccines and consumer healthcare products.